PTEN expression
|
HER2 Positive Breast Cancer
|
PTEN expression
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Resistant: B - Late Trials
|
ado-trastuzumab emtansine Resistant: B - Late Trials
|
PTEN expression
|
Breast Cancer
|
PTEN expression
|
Breast Cancer
|
trastuzumab Sensitive: C2 – Inclusion Criteria
|
trastuzumab Sensitive: C2 – Inclusion Criteria
|
PTEN expression
|
Salivary Gland Cancer
|
PTEN expression
|
Salivary Gland Cancer
|
bicalutamide Sensitive: C3 – Early Trials
|
bicalutamide Sensitive: C3 – Early Trials
|
PTEN expression
|
Salivary Gland Cancer
|
PTEN expression
|
Salivary Gland Cancer
|
trastuzumab Sensitive: C3 – Early Trials
|
trastuzumab Sensitive: C3 – Early Trials
|
PTEN expression
|
Prostate Cancer
|
PTEN expression
|
Prostate Cancer
|
leuprolide acetate + apalutamide Sensitive: C3 – Early Trials
|
leuprolide acetate + apalutamide Sensitive: C3 – Early Trials
|
PTEN expression
|
SCCHN
|
PTEN expression
|
SCCHN
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|
PTEN expression
|
Bladder Cancer
|
PTEN expression
|
Bladder Cancer
|
everolimus Sensitive: C3 – Early Trials
|
everolimus Sensitive: C3 – Early Trials
|
PTEN expression
|
CRC
|
PTEN expression
|
CRC
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|
PTEN expression
|
Breast Cancer
|
PTEN expression
|
Breast Cancer
|
GDC-0980 Sensitive: D – Preclinical
|
GDC-0980 Sensitive: D – Preclinical
|